Management of Factor V Deficiency and Factor V Leiden Mutation

Factor V Leiden Mutation Management

The American College of Medical Genetics recommends direct DNA-based genotyping or a Factor V Leiden-specific functional assay for diagnosis when clinically indicated 1
Patients who test positive by functional assay should undergo DNA testing for confirmation and to distinguish heterozygotes from homozygotes, as recommended by the American College of Medical Genetics 1
For relatives of individuals known to have Factor V Leiden, DNA testing is the preferred method, according to the American College of Medical Genetics 1
For women who are heterozygous for Factor V Leiden with a family history of VTE, antepartum antithrombotic prophylaxis is suggested, based on guidelines from the American Society of Hematology 4
For women who are homozygous for Factor V Leiden, regardless of family history, antepartum antithrombotic prophylaxis is recommended, as per guidelines from the American Society of Hematology 4
The lifetime risk for venous thrombosis in Factor V Leiden heterozygotes is approximately 10% and for homozygotes is >80%, according to the American College of Medical Genetics 7
Knowledge of Factor V Leiden status in asymptomatic relatives can guide antithrombotic prophylaxis during high-risk periods, particularly postpartum, as recommended by the American College of Medical Genetics 7

Treatment of Factor V deficiency typically involves fresh frozen plasma (FFP) administration, as there is no specific Factor V concentrate available, according to the American College of Medical Genetics 1
The management of Factor V deficiency is primarily based on bleeding risk rather than thrombotic risk, as stated by the National Hemophilia Foundation 8

Avoid routine testing for Factor V Leiden in all patients with VTE; testing should be guided by clinical presentation, age at first thrombosis, and family history, as recommended by the American College of Medical Genetics 8
The risk of major bleeding with chronic warfarin therapy may reach 8% per year, which must be balanced against thrombosis risk, according to the American Heart Association 1